Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia. (4th November 2020)

• Record Type: Journal Article
• Authors: Huschart, Emily; Miller, Holly; Salzberg, Dana; Campbell, Courtney; Beebe, Kristen; Schwalbach, Charlotte; Magee, Kyrie; Adams, Roberta H.; Ngwube, Alexander
• Is Part Of: Pediatric hematology and oncology. Volume 38:Number 2(2021)
• Page Start: 154
• Page End: 160
• Publication Date: 2020-11-04
• Subjects: AML -- azacitidine -- HSCT -- prophylactic DLI; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Hematologic Diseases -- Child; Hematologic Diseases -- Infant; Neoplasms -- Child; 618.9215
• DOI: 10.1080/08880018.2020.1829220
• Languages: English
• ISSNs: 0888-0018

Abstract

Abstract: Post-hematopoietic stem cell transplantation (HSCT) maintenance therapy using azacitidine and prophylactic donor lymphocyte infusions (DLI) was implemented for high-risk acute myeloid leukemia. Azacitidine was started on day +60 as a 5 day course every 28 days for 6 cycles. DLI was given every 6 weeks for 3 doses starting after day +120. Ten patients were treated on this protocol. With a 90% one-year disease free survival, we report this post-HSCT maintenance therapy is feasible, safe, and well tolerated.